Mikhail V. Blagosklonny of Roswell Park Cancer Institute wrote "Aging is the sum of pre-diseases and diseases."
Biochemists have elucidated a nutrient response pathway that is mechanistic target of rapamycin (mTOR). Experiments in animals have shown that when certain chemicals (drugs) are inserted that inhibit this pathway, the animals live longer and experience fewer signs of old age. These results have incited interest in developing mTOR inhibitors for use in extends lifespan in model organisms and confers protection against a growing list of age-related pathologies. mTOR inhibitors have been approved by the FDA for cancer treatment. There are none approved for general aging.
Rapamycin, Everolimus, and Temsirolimus are approved in some form. Rapamycin (also known as Sirolimus) is used to facilitate organ transplants.